ATE225658T1 - Verfahren zur senkung des intrakulären druckes im auge von säugern unter anwendung von kaliumkanalblokker - Google Patents

Verfahren zur senkung des intrakulären druckes im auge von säugern unter anwendung von kaliumkanalblokker

Info

Publication number: ATE225658T1
Authority: AT; Austria
Prior art keywords: potassium channel; eye; channel blockers; mammals; lowering
Prior art date: 1995-04-28

Application number

AT96912798T

Other languages

English (en)

Inventor

Joseph S Adorante

Elizabeth Woldemussie

Guadalupe Ruiz

Original Assignee

Allergan Sales Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-28

Filing date

1996-04-16

Publication date

2002-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23710776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE225658(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-04-16 Application filed by Allergan Sales Inc filed Critical Allergan Sales Inc

2002-10-15 Application granted granted Critical

2002-10-15 Publication of ATE225658T1 publication Critical patent/ATE225658T1/de

Links

239000003450 potassium channel blocker Substances 0.000 title abstract 2
241000124008 Mammalia Species 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 abstract 3
LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 abstract 2
108010023798 Charybdotoxin Proteins 0.000 abstract 1
235000001258 Cinchona calisaya Nutrition 0.000 abstract 1
208000010412 Glaucoma Diseases 0.000 abstract 1
241000238631 Hexapoda Species 0.000 abstract 1
206010030043 Ocular hypertension Diseases 0.000 abstract 1
HSFKQYJRJBEWKH-XTHGXZEWSA-N Paspalicine Chemical compound C1=CC=C2C(C[C@@H]3CC[C@@H]4[C@]([C@@]53C)(C)CC[C@]36OC([C@H](C(=O)C=C34)O6)(C)C)=C5NC2=C1 HSFKQYJRJBEWKH-XTHGXZEWSA-N 0.000 abstract 1
HSFKQYJRJBEWKH-UHFFFAOYSA-N Paspalicine Natural products C1=CC=C2C(CC3CCC4C(C53C)(C)CCC36OC(C(C(=O)C=C34)O6)(C)C)=C5NC2=C1 HSFKQYJRJBEWKH-UHFFFAOYSA-N 0.000 abstract 1
JDUWHZOLEDOQSR-JKPSMKLGSA-N Penitrem A Chemical compound O([C@H]1[C@H]2[C@@](C(N3)=C11)(C)[C@@]4(C)CC[C@@H]5O[C@@H]([C@@H]([C@H]6O[C@@]56[C@]4(O)CC2)O)C(=C)C)C(C)(C)[C@H]2C[C@H]4[C@]2(O)C2=C1C3=CC(Cl)=C2CC4=C JDUWHZOLEDOQSR-JKPSMKLGSA-N 0.000 abstract 1
102000004257 Potassium Channel Human genes 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
230000000903 blocking effect Effects 0.000 abstract 1
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
CNVQLPPZGABUCM-LIGYZCPXSA-N ctx toxin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]3CSSC[C@@H](C(N[C@@H](CC=4C5=CC=CC=C5NC=4)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CO)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3NC=NC=3)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N2)C(C)C)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC1=O)=O)CCSC)C(C)C)[C@@H](C)O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 CNVQLPPZGABUCM-LIGYZCPXSA-N 0.000 abstract 1
VDNVVLOBNHIMQA-UHFFFAOYSA-N iberiotoxin Chemical compound C1SSCC(C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(O)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C1NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCCNC(N)=N)NC(=O)C(CC(O)=O)NC(=O)C(C(C)C)NC(=O)CNC(=O)C(CC=1C=CC=CC=1)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CCCCN)NC1=O)CSSCC1NC(=O)C(C(C)C)NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(NC(=O)C(CCC(O)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)NC1=O)CSSCC1NC(=O)C(CC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(O)=O)NC(=O)C(C(C)O)NC(=O)C(NC(=O)C1NC(=O)CC1)CC1=CC=CC=C1 VDNVVLOBNHIMQA-UHFFFAOYSA-N 0.000 abstract 1
108010068927 iberiotoxin Proteins 0.000 abstract 1
229930005303 indole alkaloid Natural products 0.000 abstract 1
150000002475 indoles Chemical class 0.000 abstract 1
JDUWHZOLEDOQSR-UHFFFAOYSA-N penitrem A Natural products C1CC2(O)C34OC4C(O)C(C(=C)C)OC3CCC2(C)C(C(N2)=C34)(C)C1C3OC(C)(C)C1CC3C1(O)C1=C4C2=CC(Cl)=C1CC3=C JDUWHZOLEDOQSR-UHFFFAOYSA-N 0.000 abstract 1
108020001213 potassium channel Proteins 0.000 abstract 1
229960000948 quinine Drugs 0.000 abstract 1
239000003053 toxin Substances 0.000 abstract 1
231100000765 toxin Toxicity 0.000 abstract 1
108700012359 toxins Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Eye Examination Apparatus (AREA)

AT96912798T 1995-04-28 1996-04-16 Verfahren zur senkung des intrakulären druckes im auge von säugern unter anwendung von kaliumkanalblokker ATE225658T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/431,170 US5573758A (en)	1995-04-28	1995-04-28	Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
PCT/US1996/005241 WO1996033719A1 (en)	1995-04-28	1996-04-16	Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers

Publications (1)

Publication Number	Publication Date
ATE225658T1 true ATE225658T1 (de)	2002-10-15

Family

ID=23710776

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT96912798T ATE225658T1 (de)	1995-04-28	1996-04-16	Verfahren zur senkung des intrakulären druckes im auge von säugern unter anwendung von kaliumkanalblokker
AT02009867T ATE251458T1 (de)	1995-04-28	1996-04-16	Nervenschutzende für auge von säugern unter anwendung von kaliumkanalblockern

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT02009867T ATE251458T1 (de)	1995-04-28	1996-04-16	Nervenschutzende für auge von säugern unter anwendung von kaliumkanalblockern

Country Status (8)

Country	Link
US (1)	US5573758A (de)
EP (2)	EP0825863B1 (de)
JP (2)	JPH11504330A (de)
AT (2)	ATE225658T1 (de)
AU (1)	AU703241B2 (de)
DE (2)	DE69630325T3 (de)
ES (2)	ES2204879T5 (de)
WO (1)	WO1996033719A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2238702T3 (es)	1995-12-21	2005-09-01	Alcon Laboratories, Inc.	Utilizacion de ciertos compuestos de isoquinolinsulfonilo en el tratamiento de glaucomas y de isquemias oculares.
US5925342A (en) *	1996-11-13	1999-07-20	Allergan	Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US6548535B2 (en)	2000-01-18	2003-04-15	Merck & Co., Inc.	Method for treating ocular hypertension
EP1251862B1 (de) *	2000-01-18	2008-10-01	Merck & Co., Inc.	Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
DE60225420T2 (de) *	2001-01-30	2009-03-26	Merck & Co., Inc.	Verfahren zur identifizierung von maxi-k-kanal-blockern
EP1357855A2 (de) *	2001-01-30	2003-11-05	Merck & Co., Inc.	Ophthalmische zusammensetzungen zur behandlung der okularen hypertension
US20040115739A1 (en) *	2002-01-25	2004-06-17	Garcia Maria L	Method for identifying maxi-k channel blockers for use in lowering elevated intraocular pressure using hek-293 cells
US7119112B2 (en) *	2002-02-28	2006-10-10	Icagen, Inc.	Sulfonamides as potassium channel blockers
AU2003217810C9 (en) *	2002-02-28	2008-06-12	Icagen, Inc.	Methods for treating diseases related to intraocular pressure
US20050124595A1 (en) *	2002-03-15	2005-06-09	Goetz Michael A.	Compositions and methods for treating glaucoma and ocular hypertension
CA2488802A1 (en) *	2002-06-14	2003-12-24	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
WO2003105868A1 (en) *	2002-06-17	2003-12-24	Merck & Co., Inc.	Novel maxi-k channel blockers, methods of use and process for making the same
US7294646B2 (en) *	2002-06-17	2007-11-13	Merck & Co. Inc.	Maxi-k channel blockers, methods of use and process for making the same
US7196082B2 (en) *	2002-11-08	2007-03-27	Merck & Co. Inc.	Ophthalmic compositions for treating ocular hypertension
US7528163B2 (en) *	2002-11-08	2009-05-05	Merck & Co. Inc.	Ophthalmic compositions for treating ocular hypertension
AU2004226479A1 (en)	2003-03-27	2004-10-14	Evotec Oai	Ophthalmic compositions for treating ocular hypertension
CA2530081A1 (en) *	2003-07-01	2005-01-13	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
AU2004268012B2 (en) *	2003-09-02	2008-11-20	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
AU2004271978B2 (en) *	2003-09-04	2009-02-05	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
DE602004020079D1 (de) *	2003-09-04	2009-04-30	Merck & Co Inc	Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
US20050250779A1 (en) *	2004-05-04	2005-11-10	Song Zhu	Pteridinone derivatives for treating ocular hypertension
US7563816B2 (en)	2004-07-20	2009-07-21	Merck & Co. Inc.	Ophthalmic compositions for treating ocular hypertension
AU2005295831A1 (en) *	2004-10-13	2006-04-27	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
EP1802300A4 (de) *	2004-10-13	2009-05-27	Merck & Co Inc	Ophthalmische zusammensetzungen zur behandlung von augenhochdruck
JP2009533326A (ja) *	2006-03-13	2009-09-17	メルクエンドカムパニーインコーポレーテッド	高眼圧症の治療用眼科用組成物
AU2007258527A1 (en) *	2006-06-12	2007-12-21	Merck Sharp & Dohme Corp.	Ophthalmic compositions for treating ocular hypertension
EP1941876A1 (de) *	2006-12-28	2008-07-09	Lacer, S.A.	Isosorbidmononitrit Derivate zur Behandlung von der Inflammation und okularen Hypertension
EP2436387B1 (de) *	2009-05-25	2018-07-25	Celgene Corporation	Pharmazeutische zusammensetzung enthaltend crbn zur verwendung in der behandlung von krankeiten des cerebralen cortex.
CA2834535A1 (en)	2011-04-29	2012-11-01	Celgene Corporation	Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
EP3904875B1 (de)	2012-06-29	2024-11-20	Celgene Corporation	Verfahren zur bestimmung der wirksamkeit von arzneimitteln anhand von ikzf3 (aiolos)
US9587281B2 (en)	2012-08-14	2017-03-07	Celgene Corporation	Cereblon isoforms and their use as biomarkers for therapeutic treatment
EP3827836A1 (de)	2014-06-27	2021-06-02	Celgene Corporation	Zusammensetzungen und verfahren zur induktion von konformationsänderungen bei cereblon und anderen e3-ubiquitin-ligasen
WO2017117118A1 (en)	2015-12-28	2017-07-06	Celgene Corporation	Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1989010757A1 (en) *	1988-05-10	1989-11-16	Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis	New ophthalmic preparation for treating glaucoma
EP0430621A3 (en) *	1989-11-29	1992-03-04	Beecham Group P.L.C.	Process for the preparation of chiral 3,4-epoxy benzopyrans
US5512591A (en) *	1993-02-18	1996-04-30	President And Fellows Of Harvard College	Treatments for diseases characterized by neovascularization
JPH08511024A (ja) *	1993-06-08	1996-11-19	バイディファーマシューティカルズ	眼内圧を低下させる方法および組成物
US5494895A (en) *	1993-07-22	1996-02-27	Merck & Co., Inc.	Scorpion peptide margatoxin with immunosuppressant activity
GB9316111D0 (en) *	1993-08-04	1993-09-22	Pfizer Ltd	Benzopyrans

1995
- 1995-04-28 US US08/431,170 patent/US5573758A/en not_active Expired - Lifetime
1996
- 1996-04-16 EP EP96912798A patent/EP0825863B1/de not_active Expired - Lifetime
- 1996-04-16 EP EP02009867A patent/EP1243270B2/de not_active Expired - Lifetime
- 1996-04-16 DE DE69630325T patent/DE69630325T3/de not_active Expired - Lifetime
- 1996-04-16 DE DE69624234T patent/DE69624234D1/de not_active Expired - Lifetime
- 1996-04-16 AU AU55488/96A patent/AU703241B2/en not_active Ceased
- 1996-04-16 ES ES02009867T patent/ES2204879T5/es not_active Expired - Lifetime
- 1996-04-16 ES ES96912798T patent/ES2182973T3/es not_active Expired - Lifetime
- 1996-04-16 AT AT96912798T patent/ATE225658T1/de not_active IP Right Cessation
- 1996-04-16 AT AT02009867T patent/ATE251458T1/de not_active IP Right Cessation
- 1996-04-16 JP JP8532585A patent/JPH11504330A/ja not_active Withdrawn
- 1996-04-16 WO PCT/US1996/005241 patent/WO1996033719A1/en not_active Ceased
2007
- 2007-06-06 JP JP2007150243A patent/JP2007217437A/ja active Pending

Also Published As

Publication number	Publication date
DE69630325T3 (de)	2009-11-19
WO1996033719A1 (en)	1996-10-31
EP0825863A1 (de)	1998-03-04
ES2182973T3 (es)	2003-03-16
EP1243270B2 (de)	2009-03-25
EP1243270A1 (de)	2002-09-25
DE69624234D1 (de)	2002-11-14
US5573758A (en)	1996-11-12
JPH11504330A (ja)	1999-04-20
DE69630325T2 (de)	2004-07-29
EP1243270B1 (de)	2003-10-08
ES2204879T5 (es)	2009-06-19
AU5548896A (en)	1996-11-18
DE69630325D1 (de)	2003-11-13
EP0825863B1 (de)	2002-10-09
ATE251458T1 (de)	2003-10-15
JP2007217437A (ja)	2007-08-30
ES2204879T3 (es)	2004-05-01
AU703241B2 (en)	1999-03-25

Publication	Publication Date	Title
ATE225658T1 (de)	2002-10-15	Verfahren zur senkung des intrakulären druckes im auge von säugern unter anwendung von kaliumkanalblokker
ATE194081T1 (de)	2000-07-15	Verfahren zur behandlung von verletzungen retinaler ganglione mit neurotrophischem faktor aus der glialzellinie (gdnf)
ATE420857T1 (de)	2009-01-15	Prostaglandin-derivate zur behandlung von glaukom und ocularer hypertension
SE9600406D0 (sv)	1996-02-05	Novel coompounds
ATE202706T1 (de)	2001-07-15	Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
BR9712085A (pt)	2000-10-24	Inibidores de metaloprotease heterocìclicos
ATE319458T1 (de)	2006-03-15	Medizinische zusammensetzungen zur behandlung von augenerkrankungen
WO2002009702A3 (en)	2002-12-27	Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
DE68928551D1 (de)	1998-02-19	Oculare hypotensive Mittel
DE69320405D1 (de)	1998-09-24	Ophthalmische Zusammensetzungen enthaltend als Wirkstoff Vitamin-E oder Ester davon
ATE359794T1 (de)	2007-05-15	3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
DE60234919D1 (de)	2010-02-11	3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks
ATE233554T1 (de)	2003-03-15	Produkte zur behandlung von glaukoma
ATE309796T1 (de)	2005-12-15	Verfahren zur behandlung von augenerkrankungen
DE60135972D1 (de)	2008-11-13	Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
DE69011054D1 (de)	1994-09-01	Substituierte cyclohexene mit zentraler Nervensystem-Wirkung.
ATE194912T1 (de)	2000-08-15	Mittel zur vorsorge und heilung von typ i allergischen krankheiten
ATE359774T1 (de)	2007-05-15	Taurinderivate verwendbar in der behandlung von netzhauterkrankungen
ATE213634T1 (de)	2002-03-15	Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts
CA2219280A1 (en)	1996-10-31	Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
DE69829227D1 (de)	2005-04-07	Arzneimittelzusammenstellung zur behandlung des erhöhten augeninnendrucks oder des glaukom
NO911051L (no)	1991-09-17	Fremgangsmaate for fremstilling av nye ascorbinsyrederivater.
WO1998001099A3 (en)	1998-03-19	Method of treating retinal ischemia and glaucoma

Legal Events

Date	Code	Title	Description
2003-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties